Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke

Post hoc analyses of clinical trials show that PCSK9 inhibitors might lower lipoprotein(a), but whether this effect contributes to reductions in cardiovascular risk remains unknown. We aimed to assess whether genetically proxied PCSK9 inhibition influences lipoprotein(a) (Lp(a)), and whether any such effect could mediate its effects on coronary artery disease (CAD) and ischemic stroke (IS).

Source: Atherosclerosis - September 25, 2022 Category: Cardiology Authors: Gian Marco De Marchis, Tolga D. Dittrich, Rainer Malik, Annaelle V. Zietz, Lilian F. Kriemler, Brian A. Ference, Martin Dichgans, Marios K. Georgakis Source Type: research